ArticleExperimental & molecular medicine2025
The role of Ephexin1 in translation and mTOR-targeted cancer therapy.
Article in Experimental & molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated network pharmacology, transcriptomics and proteomics unveils the mechanisms of Forsythiae Fructus against acute lung injury.Die Naturwissenschaften · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ephexin1, also known as neuronal guanine nucleotide exchange factor (NGEF), plays a key role in axon guidance and synaptic homeostasis. However, our recent studies have revealed a critical role for Ephexin1 in the pathogenesis of colon and lung cancers. Here we used multidisciplinary approaches to further explore the underlying mechanisms of Ephexin1 in cancer progression. We discovered that Ephexin1 is essential for promoting polysome formation by coordinating the assembly of translation initiation complexes. Our investigations into gene expression affected by Ephexin1 deficiency showed that Ephexin1 specifically promotes the translation of genes containing 5'-terminal oligopyrimidine (TOP) or 5'-TOP-like motifs, identifying Ephexin1 as a key mediator of mTOR-regulated translation. Importantly, we found that the efficacy of mTOR inhibitors in treating lung cancer was significantly enhanced in a mouse xenograft model when Ephexin1 was deficient. This suggests that Ephexin1 could serve as a synthetic lethality target for mTORC1-targeting therapeutics in cancer treatment. Our findings provide mechanistic insights into the role of Ephexin1 in cancer pathogenesis and highlight its potential as a therapeutic target for improving current cancer treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.